TEVA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	7.21M
Average Volume	9.86M
Market Cap	18.98B
EPS	$0 ( 2024-05-08 )
Next earnings date	( $0 ) 2024-07-31
Last Dividend	$0.0850 ( 2017-11-27 )
Next Dividend	$0 ( N/A )
P/E	-40.31
ATR14	$0.0160 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-15	Weiss Amir	Sell	15 500	Ordinary Shares
2024-05-16	Weiss Amir	Sell	12 635	Ordinary Shares
2024-05-13	Conway Vikki L	Sell	15 219	Ordinary Shares
2024-03-05	Kalif Eliyahu Sharon	Buy	21 387	Ordinary Shares
2024-03-05	Kalif Eliyahu Sharon	Buy	52 320	Ordinary Shares

INSIDER POWER
9.71
Last 99 transactions
Buy: 2 018 530 \| Sell: 1 655 947

Volume Correlation

Long: 0.46 (neutral)

Short: 0.19 (neutral)

Signal:(66.797) Neutral

Teva Pharmaceutical Correlation

10 Most Positive Correlations
CACI	0.956
HWM	0.953
THC	0.952
CL	0.942
LDOS	0.941
BWLP	0.936
XYL	0.935
SF	0.932
CNDA-UN	0.931
TT	0.924

10 Most Negative Correlations
BYON	-0.946
LEG	-0.942
QBTS	-0.938
CHGG	-0.927
CCG	-0.926
AMBI	-0.92
GAM-PB	-0.918
GETR	-0.918
CRI	-0.905
MPU	-0.903

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Teva Pharmaceutical Correlation - Currency/Commodity

-0.23
( neutral )

-0.43
( neutral )

0.00
( neutral )

0.33
( neutral )

-0.04
( neutral )

Teva Pharmaceutical Financials

Annual	2023
Revenue:	$15.85B
Gross Profit:	$7.65B (48.25 %)
EPS:	$-0.500

FY	2023
Revenue:	$15.85B
Gross Profit:	$7.65B (48.25 %)
EPS:	$-0.500

FY	2022
Revenue:	$14.93B
Gross Profit:	$6.97B (46.72 %)
EPS:	$-2.12

FY	2021
Revenue:	$15.88B
Gross Profit:	$7.60B (47.83 %)
EPS:	$0.380

Financial Reports:

No articles found.

Teva Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Teva Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 3.73 - low (24.19%) | Divividend Growth Potential Score: 1.287 - No dividend growth expected in the near future

Information

First Dividend	$0.00188	1987-02-23
Last Dividend	$0.0850	2017-11-27
Next Dividend	$0	N/A
Payout Date	2017-12-12
Next Payout Date	N/A
# dividends	125	--
Total Paid Out	$11.76	--
Avg. Dividend % Per Year	0.00%	--
Score	3.25	--
Div. Sustainability Score	3.73
Div.Growth Potential Score	1.287
Div. Directional Score	2.51	--

Next Divdend (Est)
(2024-06-10)

$0 Estimate 0.00 %

Dividend Stability

0.17 Bad

Dividend Score

3.25

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1987	$0.00802	1.94%
1988	$0.00964	2.40%
1989	$0.00807	1.81%
1990	$0.00919	1.23%
1991	$0.00938	1.28%
1992	$0.0105	0.75%
1993	$0.0161	0.56%
1994	$0.0175	0.46%
1995	$0.0271	0.90%
1996	$0.0250	0.43%
1997	$0.0310	0.50%
1998	$0.0411	0.68%
1999	$0.0276	0.52%
2000	$0.0413	0.47%
2001	$0.0648	0.39%
2002	$0.0906	0.59%
2003	$0.163	0.83%
2004	$0.201	0.69%
2005	$0.269	0.92%
2006	$0.306	0.69%
2007	$0.385	1.23%
2008	$0.503	1.07%
2009	$0.605	1.42%
2010	$0.748	1.29%
2011	$0.901	1.71%
2012	$1.034	2.40%
2013	$1.278	3.44%
2014	$1.366	3.39%
2015	$1.360	2.42%
2016	$1.360	2.08%
2017	$0.850	2.27%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend King	2023-06-30	Quarterly	2	5.23%	8.53
PVL	Dividend Royal	2023-11-15	Monthly	14	9.37%	8.50
ACP	Dividend Royal	2024-05-22	Monthly	14	11.88%	8.50
ARR	Dividend Royal	2024-05-14	Monthly	15	11.08%	8.50
ACV	Dividend Royal	2024-06-13	Monthly	10	10.19%	8.50
AVK	Dividend Royal	2024-05-14	Monthly	22	9.54%	8.31
AFG	Dividend Royal	2024-04-12	Bi-Monthly	39	9.39%	8.06
JPT	Dividend King	2023-11-02	Monthly	8	4.19%	8.05
VCIF	Dividend Royal	2023-08-18	Monthly	6	8.05%	8.02
EDI	Dividend Royal	2023-12-07	Monthly	13	8.85%	7.94

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0308	1.500	-0.616	-0.923	[0 - 0.5]
returnOnAssetsTTM	-0.0115	1.200	-0.384	-0.461	[0 - 0.3]
returnOnEquityTTM	-0.0686	1.500	-1.873	-2.81	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.892	0.800	-0.542	-0.434	[1 - 3]
quickRatioTTM	0.467	0.800	-1.956	-1.565	[0.8 - 2.5]
cashRatioTTM	0.217	1.500	9.91	10.00	[0.2 - 2]
debtRatioTTM	0.459	-1.500	2.35	-3.52	[0 - 0.6]
interestCoverageTTM	1.067	1.000	-0.716	-0.716	[3 - 30]
operatingCashFlowPerShareTTM	1.500	2.00	9.50	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.045	2.00	9.48	10.00	[0 - 20]
debtEquityRatioTTM	2.70	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.490	1.000	5.17	5.17	[0.2 - 0.8]
operatingProfitMarginTTM	0.0679	1.000	-0.643	-0.643	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0857	1.000	-0.635	-0.635	[0.2 - 2]
assetTurnoverTTM	0.374	0.800	-0.837	-0.670	[0.5 - 2]
Total Score				3.73

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-38.56	1.000	-4.00	0	[1 - 100]
returnOnEquityTTM	-0.0686	2.50	-1.204	-2.81	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.045	2.00	9.65	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.500	2.00	9.50	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-1.851	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.105	1.000	9.87	0	[0.1 - 0.5]
Total Score				1.287

Teva Pharmaceutical Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Teva Pharmaceutical

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.